| Phase 16 trials |
|
Phase 1
|
NCT06905197 |
May 2025 → Sep 2027 expected |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06084104 |
Oct 2023 → Jun 2024 |
— |
Dizal Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05926180 |
Jul 2023 → May 2024 |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05418582 |
Jan → Jun 2022 |
— |
Dizal Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05159895 |
Sep 2021 → Mar 2022 |
— |
Dizal Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04909242 |
Apr 2021 → Feb 2022 |
— |
Dizal Pharmaceuticals |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT07079475 |
Jul 2025 → Jun 2028 expected |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06195189 |
Feb 2024 → Dec 2027 expected |
non-small cell lung carcinoma |
Sichuan University |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04148742 |
Aug 2021 → Jul 2023 |
B-cell non-Hodgkin lymphoma |
Dizal Pharmaceuticals |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT03974022 |
Jul 2019 → Jul 2024 overdue |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
| Phase 210 trials |
|
Phase 2
|
NCT06864624 |
Feb 2025 → Dec 2026 expected |
non-small cell lung carcinoma |
Tang-Du Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07117890 |
Feb 2025 → Feb 2027 expected |
non-small cell lung carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06563999 |
Nov 2024 → Nov 2027 expected |
lung carcinoma |
Sun Yat-sen University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07274761 |
Oct 2024 → May 2030 expected |
non-small cell lung carcinoma |
Shanghai Pulmonary Hospital, Shanghai, China |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06355609 |
Jul 2024 → Dec 2025 overdue |
non-small cell lung carcinoma |
Hunan Province Tumor Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06348927 |
Jul 2024 → Oct 2025 overdue |
non-small cell lung carcinoma |
Hunan Province Tumor Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06182761 |
Jan 2024 → Jan 2026 overdue |
non-small cell lung carcinoma |
Shanghai Zhongshan Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06295432 |
Jun 2023 → Dec 2026 expected |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06276283 |
Feb 2023 → Dec 2025 overdue |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05712902 |
Jul 2021 → Oct 2022 overdue |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07182682 |
Dec 2025 → Sep 2029 expected |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05668988 |
Dec 2022 → Jan 2026 overdue |
non-small cell lung carcinoma |
Dizal Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT05559645 |
Nov 2021 → Dec 2025 |
non-small cell lung carcinoma |
Peking Union Medical College Hospital |
Unknown
|
No outcome recorded
|